There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

Sanibel Captiva Trust Company Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.8% ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Perpetual Ltd cut its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.0% during the 3rd quarter, according to ...

While additional drugs in the same class are sure to earn FDA approval in the coming years, Eli Lilly is well positioned in the segment. Given its immense resources, it should be able to maintain a ...